about
Enhancing oral vaccine potency by targeting intestinal M cellsImmunogenicity and cross-reactivity of 2009-2010 inactivated seasonal influenza vaccine in US adults and elderlyDeveloping Universal Influenza Vaccines: Hitting the Nail, Not Just on the HeadObesity Outweighs Protection Conferred by Adjuvanted Influenza Vaccination.The Possible Impact of Vaccination for Seasonal Influenza on Emergence of Pandemic Influenza via Reassortment.Verdinexor, a novel selective inhibitor of nuclear export, reduces influenza a virus replication in vitro and in vivo.Single-Dose CpG Immunization Protects Against a Heterosubtypic Challenge and Generates Antigen-Specific Memory T Cells.Properly folded bacterially expressed H1N1 hemagglutinin globular head and ectodomain vaccines protect ferrets against H1N1 pandemic influenza virusUniversal or Specific? A Modeling-Based Comparison of Broad-Spectrum Influenza Vaccines against Conventional, Strain-Matched VaccinesEstimating Direct and Indirect Protective Effect of Influenza Vaccination in the United States.Towards universal influenza vaccines?Adverse drug events monitoring of live attenuated pandemic influenza vaccine.Influenza vaccination coverage rate in children: reasons for a failure and how to go forward.Oligomeric recombinant H5 HA1 vaccine produced in bacteria protects ferrets from homologous and heterologous wild-type H5N1 influenza challenge and controls viral loads better than subunit H5N1 vaccine by eliciting high-affinity antibodies.Recombinant parainfluenza virus 5 vaccine encoding the influenza virus hemagglutinin protects against H5N1 highly pathogenic avian influenza virus infection following intranasal or intramuscular vaccination of BALB/c mice.Pandemic influenza vaccine: characterization of A/California/07/2009 (H1N1) recombinant hemagglutinin protein and insights into H1N1 antigen stabilityProphylactic and therapeutic activity of fully human monoclonal antibodies directed against influenza A M2 protein.Central European Vaccination Advisory Group (CEVAG) guidance statement on recommendations for influenza vaccination in childrenA humanized mouse model identifies key amino acids for low immunogenicity of H7N9 vaccines.Should my patient with inflammatory bowel disease on immunosuppressive therapy be vaccinated against influenza virus?Cross-protective peptide vaccine against influenza A viruses developed in HLA-A*2402 human immunity model.Virus-vectored influenza virus vaccines.Cationic lipid/DNA complex-adjuvanted influenza A virus vaccination induces robust cross-protective immunityEvasion of natural killer cells by influenza virus.Association between use of statins and mortality among patients hospitalized with laboratory-confirmed influenza virus infections: a multistate study.Immunogenicity of a monovalent 2009 influenza A (H1N1) vaccine in an immunocompromised population: a prospective study comparing HIV-infected adults with HIV-uninfected adultsCritical role of TLR7 signaling in the priming of cross-protective cytotoxic T lymphocyte responses by a whole inactivated influenza virus vaccine.Modifications of cysteine residues in the transmembrane and cytoplasmic domains of a recombinant hemagglutinin protein prevent cross-linked multimer formation and potency lossPreclinical activity of VX-787, a first-in-class, orally bioavailable inhibitor of the influenza virus polymerase PB2 subunit.Mucosal vaccination with recombinant Lactobacillus casei-displayed CTA1-conjugated consensus matrix protein-2 (sM2) induces broad protection against divergent influenza subtypes in BALB/c mice.A Human Anti-M2 Antibody Mediates Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) and Cytokine Secretion by Resting and Cytokine-Preactivated Natural Killer (NK) CellsLung homing CTLs and their proliferation ability are important correlates of vaccine protection against influenzaApplication of real time RT-PCR for the genetic homogeneity and stability tests of the seed candidates for live attenuated influenza vaccine production.An audit of influenza vaccination status in adults with inflammatory bowel diseaseA 2013/2014 northern hemisphere season surface antigen inactivated trivalent influenza vaccine--Assessing the immunogenicity and safety in an open label, uncontrolled study.Production of H5N1 Influenza Virus Matrix Protein 2 Ectodomain Protein Bodies in Tobacco Plants and in Insect Cells as a Candidate Universal Influenza Vaccine.Immunity to the conserved influenza nucleoprotein reduces susceptibility to secondary bacterial infectionsComprehensive analysis of antibody recognition in convalescent humans from highly pathogenic avian influenza H5N1 infectionImplementation of new approaches for generating conventional reassortants for live attenuated influenza vaccine based on Russian master donor viruses.T-cell epitope vaccine design by immunoinformatics.
P2860
Q21089613-7DD77824-E244-40ED-BC51-D133CACC80CAQ21560857-85864327-AE72-4021-9A39-5E6CCAEF11E3Q26783897-75867ECB-B2C0-4F30-9870-B8C7325320FDQ30151873-B8528B15-7C14-4C9B-A1D8-C3AFDA66D212Q30205724-1684BD2E-E016-4201-A74D-62EB21BAAD28Q30363986-17A27EBB-37E0-45AD-9942-09BFF2ADD34CQ30376518-F4A586A6-EAC4-4DD7-B6C8-B6006FAA9759Q30391443-B3A4725B-3D39-4D5E-BC1D-6201400B0A94Q30396482-A3DA0A70-BC56-4962-8ADB-C9A357D95E94Q30400623-0013D24B-1CA3-4E4D-BA06-DF1992483EBFQ30406748-03BF9E0F-3401-46D4-AE05-9F53ED56F712Q30409583-FD75F06F-6639-4F24-969C-0E715754CB66Q30411868-86564770-BE13-4A5D-ACFF-405677187E0AQ30420990-31BF98A4-763B-4B2A-BEF7-C45EA68FF58CQ30422513-D3BEBE41-8F34-46C7-942A-95BD1D49D568Q30422979-ED3B9E87-5C59-4D1B-87A5-0410068DD1B0Q33582945-FC9F1BAE-F700-46C8-9D4C-F2C85A85B38AQ33603662-5F001A44-6898-4C3A-B0AA-6DBD8EB4C6CDQ33683108-6EAC25E2-26E9-4B9B-B4C1-D88A5ECA14B0Q33779792-03B1B06C-9F55-434C-AB0C-AE61DD8BE750Q34031410-1A846BB2-8D99-4866-8C08-54BDB740D9E1Q34102268-608C10F8-F3D7-4A55-91B0-E03E58C38DF0Q34416393-A95DAB1B-D2EA-4F69-900C-5DC610C80CA1Q34510128-25CEC7CD-870A-4E74-9FBE-0182AEE7665BQ34634314-7B62C588-FE77-48BB-B45D-CBE00423ED73Q34699094-87D1D91C-440C-42D1-AF43-C3463B5C9CC3Q34712969-AC596DBC-AEDD-4D8A-A89A-D83B77F001E6Q35061360-6B5DBD81-2A7C-4FD8-B1B4-E1B86860B85FQ35076802-D92AAF1D-38DF-4FC8-8E29-3A215F749C22Q35142923-49EEC2A9-2FB9-4594-8434-3F60D98AE253Q35542801-295D0201-1A6C-4918-A4DE-34AB4D252616Q35720693-0932DD14-0B44-49B9-B11D-EA958EBF7B88Q36165344-D3D82DEF-B375-4800-A4C9-20408B943A9CQ36231818-1FB66424-C8B5-414C-ADCC-816B0E8CDBA9Q36256268-5CDF37B3-7B06-426E-B564-FA8319D854C1Q36352851-A1984CA8-3901-4718-BE52-C225FA7E736AQ36374228-A466E5A1-4C9E-4FA1-A86D-79FED3A5FB05Q36392511-793F2CAD-B559-4DBB-9750-BD0418662E59Q36637886-092E7EAE-89E4-4D82-B6F0-875DD3B7106CQ36702419-FC9D71F5-0DA5-4BD1-A13B-CB90DED23FED
P2860
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Seasonal influenza vaccines.
@ast
Seasonal influenza vaccines.
@en
type
label
Seasonal influenza vaccines.
@ast
Seasonal influenza vaccines.
@en
prefLabel
Seasonal influenza vaccines.
@ast
Seasonal influenza vaccines.
@en
P2093
P1476
Seasonal influenza vaccines.
@en
P2093
Anthony E Fiore
Carolyn B Bridges
Nancy J Cox
P356
10.1007/978-3-540-92165-3_3
P577
2009-01-01T00:00:00Z